Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078691 | 0.84 | BACE1 (0.47) | BACE1NPC1MAPTRAB9APOLB | |
| SCHEMBL287239 | 0.80 | NPC1 (0.53) | NPC1MAPTRAB9APOLBASPH | |
| SCHEMBL8516575 | 0.78 | RAB9A (0.45) | BACE1NPC1MAPTRAB9ASMO | |
| SCHEMBL30492741 | 0.73 | PRMT6 (0.44) | BACE1NPC1MAPTRAB9APOLB | |
| SCHEMBL30006632 | 0.72 | ASPH (0.50) | ASPHKDM4E | |
| SCHEMBL1173916 | 0.72 | ASPH (0.50) | ASPHKDM4E | |
| SCHEMBL14152508 | 0.71 | KMT2A (0.45) | NPC1MAPTRAB9APOLBHTT | |
| SCHEMBL20187400 | 0.70 | KCNJ1 (0.51) | BACE1NPC1MAPTRAB9APOLB | |
| SCHEMBL29399915 | 0.70 | MAPT (0.51) | MAPTPOLBNPSR1HTT | |
| SCHEMBL31431338 | 0.70 | NPC1 (0.43) | NPC1MAPTRAB9APOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | claimed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | claimed |
| CN-102471293-B | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-10-01 | — | — | CN | claimed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | claimed |
| CN-103596569-A | BACE-2 inhibitors for the treatment of metabolic disorders | NOVARTIS AG | 2014-02-19 | — | — | CN | claimed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| CN-102666507-A | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2012-09-12 | — | — | CN | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | claimed |
| CN-102471293-A | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG | 2012-05-23 | — | — | CN | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| US-9687494-B2 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160367563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9475785-B2 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9428475-B2 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| US-8168630-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | BACE1 2/4885NPC1 28/4885MAPT 69/4885 |
| US-20160367563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | BACE1 1/4885NPC1 665/4885MAPT 19/4885 |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | BACE1 5/4885NPC1 1435/4885MAPT 80/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | BACE1 69/4885NPC1 1400/4885MAPT 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.